Mutational status of myeloproliferative neoplasms

Elisa Rumi, Chiara Elena, Francesco Passamonti

Research output: Contribution to journalArticle

Abstract

Philadelphia negative myeloproliferative neoplasms include essential thrombocythemia, polycythemia vera, and primary myelofibrosis. Altered signaling is a hallmark of myeloproliferative neoplasms, as demonstrated by the presence of activating JAK2 (V617F) mutation in about 70% of patients (95% of polycythemia vera, 50%-60% of essential thrombocythemia, and 50%-60% of primary myelofibrosis). How a unique point mutation can cause three different phenotypes remains to be clarified. The oncogenic potential of this mutation has been documented by mouse models, and different clinical studies have demonstrated an effect of mutant allele burden on phenotype. Mutant allele burden, in fact, directly correlates with hemoglobin value, leukocyte count, and, inversely, with platelet count. The molecular basis of JAK2 (V617F)-negative myeloproliferative neoplasms remains largely unexplained. Additional mutations in MPL, TET2, and CBL genes have been found in a small proportion of these patients. Implications of these mutations in the understanding of the pathogenesis of myeloproliferative neoplasms and in the clinical phenotype are discussed in this review.

Original languageEnglish
Pages (from-to)61-76
Number of pages16
JournalCritical Reviews in Eukaryotic Gene Expression
Volume20
Issue number1
Publication statusPublished - 2010

    Fingerprint

Keywords

  • CBL
  • JAK2
  • MPL
  • Myelofi brosis
  • Polycythemia
  • TET2
  • Thrombocythemia

ASJC Scopus subject areas

  • Genetics
  • Molecular Biology

Cite this